Lipid Lowering Drugs Flashcards

0
Q

HMG CoA Reductase Inhibitor

A

Atorvastatin (Lipitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Required Lipid Lowering drugs

A

1) Atorvastatin Calcium
2) Fenofibrate
3) Colesevelam
4) Niacin
5) Ezetimibe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Atorvastatin has a long/short half life and is metabolized how?

A

Long, 3A4 and 2C9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MOA of Atorvastatin

A
  • Completely inhibit HMG CoA reductase- blocking rate limiting step in cholesterol synthesis.
    a) Increase synthesis of hepatic LDL receptors and increase removal of LDL particles from circulation.
    b) Enhance clearance of LDL precursors (VLDL and IDL)
    c) May also decrease VLDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Statin effects on plasma lipids and lipoproteins (Atorvastatin)

A
  • Lower LDL (20-55%)
  • Trig concentration decreased (20%)
  • HDL increase (5-10%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

First line treatment for hypercholesterolemia?

A

Statin- Atorvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What other potential effects can statin have?

A

Cardioprotective effects. ie: Lowering CRP levels, anti-inflammatory, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pharmacokinetics of Statins

A

Given orally, usually in evening.

  • 1st pass metabolism by liver. Half life varies from 3-20 hours.
  • Statins are excreted by the liver into the bile
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Adverse effects of Statins

A

1) GI irritation, headache, rash
2) Hepatotoxicity
3) Myopathy
* Usually in 1st 6 mos.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Precautions and contraindications with Statins

A

1) Pregnancy and lactation

2) Liver disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Name a fibric acid

A

Fenofibrate (Tricor, Trilpix)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of fibric acids (Fenofibrate)

A

-Agonists at peroxisome proliferator activated receptor-a (PPAR-a)- Increases fatty acid oxidation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bile Acid Binding resins

A

Colesevelam (Welchol)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Fibric acids effects on plasma lipids and lipoproteins

A
  • Lower VLDL concentration, thus lowering trig concentrations.
  • Plasma HDL increases
  • Variable effects on LDL levels
  • Increase LP lipase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MOA of Bile Acid Binding resins (Colesvelam)

A

_Bind bile acid in the intestine and prevent their reabsorption.

  • This decreases the feedback inhibition of the enzyme converting cholesterol to bile acids and results in increased breakdown of hepatic cholesterol.
  • Increased catabolism of cholesterol leads to an increased number of LDL receptors, similar to statins. However, this is somewhat offset by an increase in HMG CoA reductase activity.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Effects on Plasma lipids and lipoproteins for Bile Acid Binding resins(Colesevelam)

A
  • Lower LDL levels (10-20%)
  • Small increase in HDL (5%)
  • No net effects on VLDL levels
16
Q

Niacin (Nicotinic Acid) MOA:

A

A) In adipose tissue, niacin inhibits the lipolysis of TGs by hormone-sensitive lipase, which reduces transport of free fatty acids to the liver and decreases hepatic TG synthesis.
B) In the liver, reduces TG synthesis by inhibiting both the synthesis and esterification of FA’s-lower VLDL
C) Raises HDL levels by decreasing the fractional clearance of HDL-apoA-I rather than by enhancing HDL synthesis.

17
Q

Niacin effect on plasma lipids and lipoproteins

A
  • Rapidly lowers TG levels by lowering VLDL (35-50%)
  • More slowly lowers LDL (25%)
  • Increases HDL (15-30%)
18
Q

Ezetimibe (Zetia) MOA:

A

1) Inhibits the intestinal absorption of cholesterol and

2) Inhibits reabsorption of cholesterol excreted in the bile. Inhibits cholesterol transport protein, NPC1L1

20
Q

Ezetimibe Effect on Plasma lipids and lipoproteins

A

-Primary effect is to reduce LDL levels (18-25%)

21
Q

Therapeutic use of Fibric Acids (Fenofibrate)

A

Patients with elevated Trigs

22
Q

Adverse effects of Fibric Acids (Fenofibrate)

A

GI, Myositis (with statins)

23
Q

Bile Acid Binding Resins (Colesevelam) uses

A

-Best used with statins

24
Q

Bile Acid Binding Resins (Colesevelam) Adverse effects

A

GI (bloating, dyspepsia, and constipation).

-Mild steatorrhea

25
Q

Niacin therapeutic uses

A

Patients with hypertriglyceridemia and elevated LDLs.

-Especially useful in pts with hyper trigs and low HDL

26
Q

Niacin adverse effects

A

1) Intense cutaneous flush and pruritis with initial doses.
2) GI disturbances
3) More severe, less frequent include hepatic toxicity, activation of peptic ulcer, hyperglycemia, and decreased glucose tolerance, and hyperuricemia.

27
Q

Ezetimibe uses

A

Adjunct with statins to reduce LDL levels. Used alone if patients intolerant to statins.

28
Q

Adverse effects of Ezetimibe

A

Diarrhea, low incidence of reversible impaired hepatic function.